Literature DB >> 3398696

A1 and A2 adenosine receptor regulation of erythropoietin production.

M Ueno1, J Brookins, B Beckman, J W Fisher.   

Abstract

The effects of adenosine (ADE) and ADE agonists on erythropoietin (Ep) production were determined using percent (%) 59Fe incorporation in red cells of exhypoxic polycythemic mice. The hemisulfate salt of ADE produced a significant increase in % 59Fe incorporation in response to hypoxia in concentrations of 400 to 1600 nmol/kg/day (i.v.). 5'-N-ethyl-carboxamideadenosine (NECA), a selective A2 receptor agonist, increased radioiron incorporation in a dose-dependent manner (10-100 nmol/kg/day, i.v.). In contrast, N6-cyclohexyladenosine (CHA), a selective A1 receptor agonist, did not affect radioiron incorporation in concentrations up to 1600 nmol/kg/day (i.v.). Albuterol, a beta 2-adrenergic agonist, enhanced % 59Fe incorporation in polycythemic mice and low doses of CHA (50 and 100 nmol/kg/day), which were not effective alone on % 59Fe incorporation in polycythemic mice exposed to hypoxia, inhibited the enhancement in radioiron induced by albuterol (25 and 100 micrograms/kg/day, i.p.) plus hypoxia. Theophylline (20 and 80 mg/kg/day, i.p.), a well-known antagonist of ADE receptors, blocked the ADE and NECA enhancement in radioiron incorporation at a dose of theophylline alone which produced only a slight enhancement of % 59Fe incorporation. These results suggest that ADE may both inhibit through A1 receptor activation and increase via A2 receptor stimulation the production of Ep.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3398696     DOI: 10.1016/0024-3205(88)90312-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Immunolocalization of ecto-5'-nucleotidase in the kidney by a monoclonal antibody.

Authors:  R Gandhi; M Le Hir; B Kaissling
Journal:  Histochemistry       Date:  1990

Review 2.  Adenosine and the adaptation to exercise.

Authors:  R E Simpson; J W Phillis
Journal:  Sports Med       Date:  1993-04       Impact factor: 11.136

Review 3.  Role of erythropoietin in adaptation to hypoxia.

Authors:  H Scholz; H J Schurek; K U Eckardt; C Bauer
Journal:  Experientia       Date:  1990-12-01

4.  Efficacy of enalapril after ineffective theophylline treatment on erythrocytosis after renal transplantation.

Authors:  T Yagisawa; H Toma; H Yaguchi; M Tomaru; Y Iijima; H Suzuki; T Nakada
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 5.  Adenosine in exercise adaptation.

Authors:  R E Simpson; J W Phillis
Journal:  Br J Sports Med       Date:  1992-03       Impact factor: 13.800

6.  Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists.

Authors:  K A Jacobson; C Gallo-Rodriguez; N Melman; B Fischer; M Maillard; A van Bergen; P J van Galen; Y Karton
Journal:  J Med Chem       Date:  1993-05-14       Impact factor: 7.446

7.  Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants.

Authors:  S Fang; R A Sherwood; H R Gamsu; J T Marsden; T J Peters; A Greenough
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

Review 8.  Erythropoietin (epoetin) as a protective factor for the brain.

Authors:  Samit Malhotra; Sheetal Nijhawan; Daniel M Rosenbaum
Journal:  Curr Atheroscler Rep       Date:  2004-07       Impact factor: 5.113

9.  Theophylline treatment may adversely affect the anoxia-induced erythropoietic response without suppressing erythropoietin production.

Authors:  Argirios E Tsantes; Stergios T Tassiopoulos; Stefanos I Papadhimitriou; Stefanos Bonovas; Nikolaos Poulakis; Athina Vlachou; Kalitsa Filioussi; Dimitrios Loukopoulos
Journal:  Eur J Clin Pharmacol       Date:  2003-08-05       Impact factor: 2.953

Review 10.  Anemia in Chronic obstructive pulmonary disease: Prevalence, pathogenesis, and potential impact.

Authors:  Malay Sarkar; Puja Negi Rajta; Jasmin Khatana
Journal:  Lung India       Date:  2015 Mar-Apr
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.